i totally agree. i doubt the FDA will approve cladribine without an additional study. also, does anyone know how many patients went on Rebif from placebo? i don't think the presenter answered that question at the CLARITY presentation.
all these new oral agents seem to carry a lot of risk, but if ppl are willing to prescribe Tysabri, then maybe they'll be comfortable with these new oral agents.
FTY720, more long term safety data than cladribine.
one thing i'm trying to figure out is ACOR. street seems mixed on the drug's chances at approval. has anyone seen that Leerink report? highlighted some good issues re: RTF.
Market Data 
Markets 
AI
